Low Frequency of Integrase Inhibitor Resistance Mutations Among Therapy-Naive HIV Patients in Southeast China.
PMID: 33679129
2021
Drug design, development and therapy
Discussion: E157Q has been shown to act as a compensatory mutation due to its ability to restore damaged enzymatic activity caused by N155H or R263K substitution.
No difference in HIV-1 integrase inhibitor resistance between CSF and blood compartments.
PMID: 33693680
2021
The Journal of antimicrobial chemotherapy
Abstract: The HIV-1 integrase sequences from CSF presented resistance mutations for 9/27 (33.3%) and 8/32 (25.0%) for ARV-naive (L74I, n = 3; L74I/M, n = 1; T97A, n = 1; E157Q, n = 4) and ARV-treated (L74I, n = 6; L74M, n = 1; T97A, n = 1; N155H, n = 1) patients, respectively.
Short Communication: Integrase Strand Transfer Inhibitors Drug Resistance Mutations in Puerto Rico HIV-Positive Individuals.
PMID: 33800269
2021
International journal of environmental research and public health
Abstract: We identified the Q148HKR, G140S, Y143R, N155H, S147G, and E138EA major drug resistance mutations and the D232DN, T97TA, E157Q, G163GART accessory mutations.
Result: The most frequent integrase mutations in our analyzed patient samples were the Q148HKR (31%), G140S (28%), and, although at lower frequencies, we were able to identify the N155H, S147G, Y143R, and
HIV-1 Subtype C Drug Resistance Mutations in Heavily Treated Patients Failing Integrase Strand Transfer Inhibitor-Based Regimens in Botswana.
Result: Amongst the individuals previously exposed to RAL ART (seven out of eleven), DRMs selected whilst failing their current DTG based regimens were E138K, G140A, Q148R; and N155H Figure 3.
Discussion: Comparable with others, amongst individuals with prior exposure to RAL, the most common mutations selected were N155H (n = 4), Q148R (n = 4), S147G (n = 4) and E138K (n = 3) as others have similarly found.
Discussion: In our study, E138K (n = 5), S147G (n = 4), Q148R (n = 4) and N155H (n = 4) where the most frequent INSTI D
High-level resistance to bictegravir and cabotegravir in subtype A- and D-infected HIV-1 patients failing raltegravir with multiple resistance mutations.
PMID: 34453542
2021
The Journal of antimicrobial chemotherapy
Abstract: RESULTS: HIV-1 IN-recombinant viruses harbouring single primary mutations (N155H or Y143R/S) or in combination with secondary INSTI mutations (T97A, M50I, L74IM, E157Q, G163R or V151I) were susceptible to both bictegravir and cabotegravir.
Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV.
Method: Patients with the following baseline mutations associated with reduced susceptibility to DTG: T66K, E92Q, G118R, E138 K/A/T, G140 S/A/C, Q148 H/R/K, N155H and R263K were excluded.
HIV Pretreatment Drug Resistance Trends in Mexico City, 2017-2020.
Result: Of note, no cases of bictegravir or dolutegravir resistance were observed among prior ARV-exposed participants (only 1 participant (0.7%) showed cabotegravir resistance due to the N155H mutation).
A Combination of M50I and V151I Polymorphic Mutations in HIV-1 Subtype B Integrase Results in Defects in Autoprocessing.
Result: After initial quality analysis, we excluded 27 sequences from four patients that contained integrase inhibitor (INI)-resistant mutations (Y143C/H/R; Q148H/K/R or N155H/S).
Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting.
PMID: 34651192
2021
The Journal of antimicrobial chemotherapy
Abstract: Among subjects receiving dolutegravir/rilpivirine, two genotypes harboured emerging RAMs at VF: E138K on NNRTI (n = 1); and E138K+K101E on NNRTI and N155H on INSTI (n = 1).
Cellular Immune Response Induced by DNA Immunization of Mice with Drug Resistant Integrases of HIV-1 Clade A Offers Partial Protection against Growth and Metastatic Activity of Integrase-Expressing Adenocarcinoma Cells.
Result: Using this gene as a platform, we further designed IN variants harboring two sets of mutations conferring resistance to RAL, one with primary resistance mutation N155H and secondary mutations
Discussion: We synthesized an expression optimized gene encoding consensus integrase (IN) of HIV-1 clade A, and using it as a platform, two drug resistant variants with alternative patterns of resistance to raltegravir combining primary and early occurring secondary/adaptive mutations L74M/E92Q/V151I/N155H/G163R (IN_r1_in) or E138K/G140S/Q148K (IN_r2_in).
HIV mutation literature information.
PMID: 
2021
Drug design, development and therapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT